MX2019000415A - Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. - Google Patents

Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.

Info

Publication number
MX2019000415A
MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A
Authority
MX
Mexico
Prior art keywords
dna vaccine
cancer immunotherapy
production
present
transformed cell
Prior art date
Application number
MX2019000415A
Other languages
English (en)
Spanish (es)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of MX2019000415A publication Critical patent/MX2019000415A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2019000415A 2016-07-13 2017-07-12 Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. MX2019000415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16001550 2016-07-13
PCT/EP2017/067590 WO2018011289A1 (en) 2016-07-13 2017-07-12 Process for the production of a dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2019000415A true MX2019000415A (es) 2019-03-28

Family

ID=56418345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000415A MX2019000415A (es) 2016-07-13 2017-07-12 Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.

Country Status (13)

Country Link
US (2) US10821163B2 (enExample)
EP (1) EP3484503A1 (enExample)
JP (2) JP7098599B2 (enExample)
KR (2) KR20190027834A (enExample)
CN (1) CN109475614A (enExample)
AU (1) AU2017295004B2 (enExample)
BR (1) BR112019000657A2 (enExample)
CA (1) CA3028549A1 (enExample)
IL (1) IL263568A (enExample)
MX (1) MX2019000415A (enExample)
RU (1) RU2019100079A (enExample)
SG (1) SG11201811258UA (enExample)
WO (1) WO2018011289A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7712060B2 (ja) * 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規vegfr-2ターゲット免疫療法アプローチ
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN118147029A (zh) 2018-07-11 2024-06-07 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR20220128638A (ko) 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
WO2024005122A1 (ja) * 2022-06-30 2024-01-04 株式会社島津製作所 微生物の分析の準備方法、および、微生物の分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360823B (es) * 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
US9493738B2 (en) * 2011-12-22 2016-11-15 Vaximm Ag Method for producing high yield attenuated Salmonella strains
EP3603664A1 (en) 2012-07-05 2020-02-05 Vaximm AG Dna vaccine for use in pancreatic cancer patients
ES2675020T3 (es) * 2013-04-25 2018-07-05 Vaximm Ag Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms
SG11201604911VA (en) * 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine

Also Published As

Publication number Publication date
BR112019000657A2 (pt) 2019-04-24
AU2017295004B2 (en) 2020-08-13
AU2017295004A1 (en) 2019-01-03
RU2019100079A (ru) 2020-08-13
KR20190027834A (ko) 2019-03-15
US20190183996A1 (en) 2019-06-20
WO2018011289A1 (en) 2018-01-18
US11590215B2 (en) 2023-02-28
CN109475614A (zh) 2019-03-15
EP3484503A1 (en) 2019-05-22
US20220072112A1 (en) 2022-03-10
JP2022097591A (ja) 2022-06-30
US10821163B2 (en) 2020-11-03
CA3028549A1 (en) 2018-01-18
JP2019521154A (ja) 2019-07-25
JP7098599B2 (ja) 2022-07-11
IL263568A (en) 2019-01-31
KR20230079514A (ko) 2023-06-07
SG11201811258UA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2019000415A (es) Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.
MY189338A (en) Method for treating cancer
MX2019011916A (es) Anticuerpos anti-lag3.
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
PH12016502505B1 (en) Bispecific t cell activating antigen binding molecules
PH12015501906A1 (en) Strain having enhanced l-valine productivity and l-valine production method using the same
MX2018003631A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
MY183219A (en) Transformant for expressing cis-prenyltransferase and nogo b receptor
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
PH12019502274A1 (en) Antibodies binding to steap-1
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
PH12017500722B1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2019227106A9 (en) Tumor-specific neoantigens and methods of using the same
MX2019000326A (es) Estera de fibra de carbono aleatoria y material compuesto de fibra de carbono.
MX2019012882A (es) Cepa de microbacterium y metodo para producir psicosa utilizando la misma.
EP4235680A3 (en) Method and apparatus for compact representation of bioinformatics data
EA201791423A1 (ru) Способ получения белка
MX2019013750A (es) Un metodo para producir ranibizumab humanizado recombinante replegado.
MY208508A (en) Nasal hepatitis b vaccine composition and method for producing same
MY189781A (en) Method for preparing polythiols
MY188494A (en) High-growth enterovirus 71 strains and vaccines
MY177218A (en) Method for producing specific ?,?-unsaturated aldehydes by rearrangement process
MY177060A (en) A process for heating an atr